This observation can be attributed to the fact that PD-1 antibodies can block the binding of PD-1 to both PD-L1 and PD-L2, thus more fully inhibiting the occurrence of immune escape, leading to better treatment outcomes for patients with advanced cancers, including non-small cell lung cancer[43]. Here, PDCD1 is linked to non-small cell lung carcinoma.